Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LYPHOMED TO MARKET CARDIADEN (ADENOSINE)

Executive Summary

LYPHOMED TO MARKET CARDIADEN (ADENOSINE) under an agreement with Medco Research, Inc., the firm announced Nov. 11. The agreement gives LyphoMed exclusive manufacturing and marketing rights in the U.S. and Canada to the injectable cardiovascular drug being studied for treatment of supraventricular tachycardia. Medco will sponsor and direct the research program for marketing approvals and receive royalties from LyphoMed. Medco Research President Manfred Mosk noted that an IND for Cardiaden was filed in October and clinicals are expected to begin in four to five weeks. LyphoMed said it anticipates completion of clinical trials "in approximately eight months" and expects to market Cardiaden "in the second quarter of 1987." LyphoMed Chairman and President John Kapoor stated that "Cardiaden has the potential of capturing the increasingly lucrative market now dominated by verapamil. This opportunity enhances and complements LyphoMed's existing manufacturing and marketing expertise and positions the company to play an increasingly important role in patented or exclusive pharmaceuticals in the years ahead." LyphoMed's release said both companies believe Cardiaden "has the potential to reach $15 mil. in sales." The Los Angeles, Calif.-based Medco Research licensed adenosine from the University of Virginia. It is the second heart drug Medco has sponsored. In November 1981, the company obtained sponsorship of Napa (acecainide) under an agreement with American Hospital Supply. Mosk said Napa has just entered Phase III clinicals. Mosk also reported that Warner-Lambert, which owns approximately 6% of Medco's total issued and common stock, obtained world-wide marketing rights to Napa about six months ago.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel